InspireMDNSPR
NSPR
About: InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Employees: 66
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
17% more funds holding
Funds holding: 30 [Q4 2024] → 35 (+5) [Q1 2025]
4% more capital invested
Capital invested by funds: $33.4M [Q4 2024] → $34.7M (+$1.34M) [Q1 2025]
5.23% less ownership
Funds ownership: 48.74% [Q4 2024] → 43.51% (-5.23%) [Q1 2025]
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
69%
upside
Avg. target
$4
69%
upside
High target
$4
69%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Adam Maeder | 69%upside $4 | Overweight Maintained | 12 May 2025 |
Financial journalist opinion
Based on 4 articles about NSPR published over the past 30 days
Positive
Zacks Investment Research
15 hours ago
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
Neutral
GlobeNewsWire
2 days ago
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA). The CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emboli against the arterial wall while preserving external carotid artery perfusion.
Neutral
GlobeNewsWire
2 weeks ago
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States.
Neutral
GlobeNewsWire
4 weeks ago
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS.
Neutral
GlobeNewsWire
1 month ago
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr.
Neutral
Seeking Alpha
2 months ago
InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Webb Campbell – Gilmartin Group LLC Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Shane Gleason – Chief Commercial Officer Conference Call Participants Adam Maeder – Piper Sandler Frank Takkinen – Lake Street Capital Operator Good morning, and welcome to InspireMD's First Quarter 2025 Earnings Conference call. [Operator Instructions] We will facilitating a question-and-answer session towards the end of today's call.
Negative
Zacks Investment Research
2 months ago
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
InspireMD Reports First Quarter 2025 Financial Results
Management to host investor conference call today, May 9th, at 8:30am ET Management to host investor conference call today, May 9th, at 8:30am ET
Neutral
GlobeNewsWire
2 months ago
InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference
MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time.
Neutral
GlobeNewsWire
2 months ago
InspireMD to Announce First Quarter 2025 Financial Results
MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Charts implemented using Lightweight Charts™